Buy Darzalex 100 mg in UK | Ernest Oncology – Bulk Supplier India

Darzalex 100 mg Injection: Advanced CD38-Targeted Therapy for Multiple Myeloma

Are you looking for a globally recognized Darzalex 100 mg injection exporter from India? Ernest Oncology, a specialized division of the Group of Ernest Pharmaceutical Pvt. Ltd., is a leading bulk supplier and distributor of high-value oncology biologics. We facilitate a seamless, cold-chain-compliant supply network for Darzalex (Daratumumab) to Washington (USA), London (UK), Canberra (Australia), and Johannesburg (South Africa), ensuring that critical immunotherapy reaches treatment centers with 100% molecular integrity.

Comprehensive Product Information: What is Darzalex 100 mg?

Darzalex 100 mg Injection is a revolutionary human monoclonal antibody (IgG1κ) used primarily in the treatment of Multiple Myeloma and AL Amyloidosis. The active ingredient, Daratumumab, targets specific proteins on the surface of cancer cells to trigger their destruction. Developed by Janssen (Johnson & Johnson), it is now a cornerstone of modern hematologic oncology.

1. Therapeutic Indications

Darzalex is clinically approved for several stages of Multiple Myeloma:

• Newly Diagnosed: For patients who are eligible or ineligible for autologous stem cell transplant (ASCT), typically used in combination with regimens like VRd (bortezomib, lenalidomide, dexamethasone).

• Relapsed/Refractory: For patients who have received at least one prior therapy, often combined with carfilzomib or pomalidomide.

• Monotherapy: For heavily pre-treated patients who have exhausted other options.

• AL Amyloidosis: The first FDA-approved treatment for light chain amyloidosis.

2. Mechanism of Action: The Multi-Pronged Attack

Daratumumab is a CD38-directed cytolytic antibody. It works by binding to the CD38 protein, which is highly expressed on the surface of multiple myeloma cells. Once bound, it destroys the cancer through the following:

• Direct On-Cell Killing: Inducing apoptosis (programmed cell death) in the myeloma cell.

• Immune-Mediated Destruction: Recruiting Natural Killer (NK) cells and macrophages to engulf and destroy the targeted cells.

• Complement-Dependent Cytotoxicity (CDC): Activating the "complement system" in the blood to punch holes in the cancer cell membrane.

3. Administration and Dosage

• Strength: 100 mg / 5 mL (20 mg/mL concentrate for solution).

• Route: Intravenous (IV) infusion by a healthcare professional.

• Schedule: Generally administered weekly for the first 8 weeks, followed by biweekly and then monthly cycles depending on the specific regimen.

Ernest Oncology: Your Global Supply Partner in 2026

In 2026, the global oncology landscape demands supply chain resilience. We prioritize:

• Authenticity: 100% genuine Janssen-manufactured Darzalex with verified batch traceability.

• Cold-Chain Excellence: Continuous monitoring (2°C to 8°C) from our GMP-certified facilities in India to your clinic door in the USA, UK, or Australia.

• Regulatory Support: Comprehensive documentation, including Certificate of Analysis (COA) and export permits for South African health authorities (SAHPRA).